Novo Nordisk honored by National Hemophilia Foundation
PRINCETON, N.J. — Danish drug maker Novo Nordisk has received the Corporate Leadership Award from the National Hemophilia Foundation in response to its research and development efforts for the disease, the company said Friday.
Novo Nordisk president Jurek Gruhn accepted the award at the NHF’s Inaugural Spring Soiree Benefit in New York Thursday. Novo Nordisk makes NovoSeven RT (coagulation factor VIIa [recombinant], room temperature stable), used to treat hemophilia A and B.
“We are honored by this recognition and are pleased to support NHF in its continued efforts to build a national movement toward better patient care in hemophilia,” Novo Nordisk corporate VP biopharmaceuticals Eddie Williams said. “We look forward to many more years of continued research, innovative treatments and initiatives to help improve the lives of patients.”
The company said it was dedicated to making advancements in strengthening the understanding of hemophilia in the broader society, improving access to diagnosis and patient care, and advancing treatment through innovation. It also supports SevenSecure, a program that offers access to financial, educational and medical support and provides funding for the Inhibitor Education Summits, designed for people living with hemophilia.
Hi-Tech granted tentative approval for generic Levaquin
AMITYVILLE, N.Y. — The Food and Drug Administration has granted tentative approval to a generic antibiotic made by Hi-Tech Pharmacal, the drug maker said Friday.
Hi-Tech announced the tentative approval of levofloxacin oral solution in the 25 mg-per-mL strength. The drug is used to treat mild, moderate and severe bacterial infections in adults.
Levofloxacin oral solution is a generic version of Johnson & Johnson’s Levaquin. Levaquin had sales of $6 million in 2010, according to IMS Health. Levaquin expects to receive final approval in June, when Johnson & Johnson’s patent expires.
Impax, Banner to develop two softgel capsule products
HAYWARD, Calif., and HIGH POINT, N.C. — Impax Labs will collaborate with a specialty pharmaceutical company dedicated to the research, development and manufacturing of unique gelatin-based dosage forms.
Impax said it has entered a deal with Banner Pharmacaps in respect to the supply and commercialization of two softgel capsule products.
The products and terms of the agreement were not disclosed.